Medicaid Provider SpendingClaims paid 2018–2024 · HHS public file
Home › NJ › Monmouth Junction › NPI 1306439138
Lab

Genophyll Enterprises LLC

Genophyll Enterprises LLC was paid $207K by Medicaid between Apr 2021 and Dec 2024, across 11 billing codes. Its largest line is U0003, Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r — 53% of everything it billed.

33Billing provider infoGENOPHYLL ENTERPRISES LLC
MONMOUTH JUNCTION, NJ 08852
33aNPI1306439138assigned 02/12/2021
28Total paid$207K
24GClaims9,946
24DCodes billed11
24AFirst – last monthApr 2021 – Dec 2024
Compared with peers

Next to other Clinical Medical Laboratory providers in New Jersey

Rank by total paid#82 of 122
Median peer was paid$1.29M
This provider vs. median0.2×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Box 24A · Dates of service

Paid by month

$0$10K$20K$30K2018201920202021202220232024
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
YearClaimsPaid
20212,511$92K
20222,997$72K
20231,368$13K
2024incomplete3,070$30K
Box 24 · Service lines

What it billed for

CodeServiceShareClaimsBene. recordsPaid
U0003 Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r 53% 1,969 1,706 $110K
U0005 Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 18% 2,005 1,741 $37K
87637 Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV 16% 3,025 1,555 $33K
G2023 Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source 12% 1,956 1,701 $26K
87798 Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism <1% 220 182 $1K
87481 <1% 177 161 $456.15
87799 <1% 139 122 $68.54
87640 <1% 177 161 $56.14
87653 <1% 177 161 $56.14
87632 0% 67 63 $0.00
87635 Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe 0% 34 23 $0.00

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.

From NPPES

Who's on the registration

Authorized officialLUTHRA, ADITI (CEO)